Skip to content

Treatment of Indigestion by Unani medicine Jawarish Pudina Wilayati

Clinical Validation of Unani Pharmacopoeial Formulation Jawarish Pudina Wilayati in Suâ?? al-Hadm (Dyspepsia)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/02/023637
Enrollment
300
Registered
2020-02-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K30- Functional dyspepsia

Interventions

Intervention1: Jawarish Pudina Wilayati: 5 gm twice daily orally to be taken with plain water after meals for six weeks Control Intervention1: Nil: Nil

Sponsors

Central Council for Research in Unani Medicine CCRUM New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex in the age group of 18-60 years 2. Patients meeting the following Rome III diagnostic criteria for post prandial distress syndrome : Symptom onset greater than 6 months prior to the diagnosis, with the following criteria fulfilled for the past 3 months: 3. No structural disease by upper endoscopy to explain the symptoms 4. At least one of the following symptoms: a. Bothersome postprandial fullness b. Early satiation c. Epigastric pain d. Epigastric burning At least one of the following: 5. Bothersome postprandial fullness after ordinary sized meals occurring at least several times a week 6. Early satiation that prevents finishing a regular meal at least several times a week

Exclusion criteria

Exclusion criteria: 1. Patients showing alarm symptoms (weight loss, anaemia, haematemesis, melaena, dysphagia, palpable abdominal mass) 2. Having any systemic disease requiring long term treatment 3. History of surgery related with the gastrointestinal tract more than six months 4. Pregnancy and lactation

Design outcomes

Primary

MeasureTime frame
Improvement in signs and symptoms of Suâ?? al-Hadm (Dyspepsia)Timepoint: Six Weeks

Secondary

MeasureTime frame
Haematological and biochemical assessment for safety assessmentTimepoint: Investigations will be done at baseline and end of treatment

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026